GlassScriptPhysician profile
Robert J Kaplan
NPI 1750359543
$8,781.39
in general payments reported to CMS, 2019-2025
29 companies · $604 in 2025
The $604 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,201 · 2020: $1,200 · 2021: $1,590 · 2022: $820 · 2023: $1,040 · 2024: $1,326 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,969.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,525.23 | 2019-2025 | Ilumya, Winlevi |
| Novartis Pharmaceuticals Corporation | $1,250.96 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $677.81 | 2019-2023 | |
| Genzyme Corporation | $541.49 | 2019-2025 | |
| Abbvie INC. | $540.75 | 2019-2024 | |
| Dermavant Sciences, INC. | $535.86 | 2022-2024 | Vtama |
| Janssen Scientific Affairs, LLC | $478.16 | 2019-2024 | Tremfya |
| Merz North America, INC. | $469.05 | 2019-2021 | |
| Pfizer INC. | $441.91 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $280.35 | 2023-2024 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $276.48 | 2019-2025 | Jublia, Cabtreo, Arazlo |
| Janssen Biotech, INC. | $250.35 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Medimetriks Pharmaceuticals, INC. | $228.42 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $176.53 | 2021-2025 | Nuzyra |
| Ucb, INC. | $158.82 | 2020-2025 | Bimzelx |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $141.32 | 2019-2021 | |
| Dermira, INC. | $128.36 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $101.87 | 2020-2021 | |
| Almirall LLC | $93.22 | 2019 | |
| Galderma Laboratories, L.P. | $90.70 | 2019-2020 | |
| Biofrontera INC. | $83.04 | 2019-2022 | |
| Lilly USA, LLC | $75.17 | 2024-2025 | Taltz, Ebglyss |
| Melinta Therapeutics, LLC | $64.68 | 2019 | |
| Dusa Pharmaceuticals, INC. | $43.50 | 2019 | |
| Arcutis Biotherapeutics, INC. | $38.19 | 2023-2024 | Zoryve |
| Sandoz INC. | $30.20 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $22.43 | 2020 | |
| Strata Skin Sciences, INC. | $19.28 | 2019 | |
| Organon LLC | $17.26 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.